ABSTRACT: Background: Assessing the impact of glioma location on prognosis remains elusive. We approached the problem using multivoxel proton magnetic resonance spectroscopic imaging ( 1 H-MRSI) to define a tumor "metabolic epicenter", and examined the relationship of metabolic epicenter location to survival and histopathological grade. Methods: We studied 54 consecutive patients with a supratentorial glioma (astrocytoma or oligodendroglioma, WHO grades II-IV). The metabolic epicenter in each tumor was defined as the 1 H-MRSI voxel containing maximum intra-tumoral choline on preoperative imaging. Tumor location was considered the X-Y-Z coordinate position, in a standardized stereotactic space, of the metabolic epicenter. Correlation between epicenter location and survival or grade was assessed. Results: Metabolic epicenter location correlated significantly with patient survival for all tumors (r 2 = 0.30, p = 0.0002) and astrocytomas alone (r 2 = 0.32, p = 0.005). A predictive model based on both metabolic epicenter location and histopathological grade accounted for 70% of the variability in survival, substantially improving on histology alone to predict survival. Location also correlated significantly with grade (r 2 = 0.25, p = 0.001): higher grade tumors had a metabolic epicenter closer to the midpoint of the brain. Conclusions: The concept of the metabolic epicenter eliminates several problems related to existing methods of classifying glioma location. The location of the metabolic epicenter is strongly correlated with overall survival and histopathological grade, suggesting that it reflects biological factors underlying glioma growth and malignant dedifferentiation. These findings may be clinically relevant to predicting patterns of local glioma recurrence, and in planning resective surgery or radiotherapy.
Supratentorial gliomas are the most frequently diagnosed primary brain tumors in adults. 1 Despite representing only 1.5% of all malignancies, 2 they are a significant cause of cancerrelated death in the general population. 3 As a result, a considerable body of research has focused on identifying prognostic markers for patients with these tumors. Although no list of such markers is universally accepted, many authors consistently agree that histopathological grade, [4] [5] [6] [7] patient age, [8] [9] [10] [11] [12] and Karnofsky Performance Status (KPS) 1 are among the most important predictors of response to therapy and outcome. Previous studies have attempted to examine the impact of the location of supratentorial gliomas on prognosis, but have come to conflicting conclusions because a universally accepted method for classifying glioma location is lacking. 13 Most frequently, gliomas have been grouped according to the cerebral lobes (frontal, parietal, temporal, or occipital) that they occupy. Such an approach is flawed because tumors crossing lobar boundaries and occupying portions of more than one lobe may be misclassified. The approach is doubly inaccurate because it fails to account for the considerable regional heterogeneity in growth characteristics and aggressive potential often observed within a given glioma.
14 Consequently, defining glioma location in a biologically relevant manner, using a precise and quantitative classification system, might increase its prognostic significance while potentially furthering our overall understanding of how gliomas grow and spread.
Proton magnetic resonance spectroscopy ( 1 H-MRS) is a noninvasive means of assessing metabolite concentrations in brain tumor tissue in vivo. Single voxel 1 H-MRS, which can determine the metabolite profile across a single large region of a tumor, improves on the diagnostic specificity of conventional magnetic resonance imaging (MRI) for supratentorial glioma. [15] [16] [17] [18] Since the early 1990s, multivoxel 1 H-MRS imaging, which elucidates metabolite concentrations within small individual volume units (voxels) within a tumor, has allowed regional metabolic variations within gliomas to be assessed. Intratumoral variations in choline (Cho) have been of particular interest. Cho is a metabolic marker of cell membrane turnover and cellular proliferation, [18] [19] [20] [21] [22] [23] [24] and a higher total Cho concentration within a glioma may be associated with increasing grade. [25] [26] [27] Early work using 1 H-MRSI suggested that the "hottest" Cho region within a tumor may represent the site of highest tumor malignancy. 27 This suggestion has since been supported by studies reporting that cellular proliferative activity within biopsy specimens, as measured by the Ki-67 labeling index, is correlated with Cho concentration in 1 H-MRSI voxels corresponding to biopsy location. 23, 25, 28, 29 Presumably, gliomas which appear to arise from the same part of the brain may actually have very different patterns of intratumoral proliferative activity as represented by their intratumoral distribution of Cho. These different patterns of intratumoral metabolism may in turn produce different clinical courses and portend different prognoses. Consequently, we decided to define the location of a glioma as the location of its point of maximum proliferative activity, represented by the 1 H-MRSI voxel containing maximum intratumoral concentration of Cho. We called this voxel the "metabolic epicenter", and defined its location as its X-Y-Z coordinate position in a standardized stereotactic coordinate space.
Based on this novel definition, the objectives of this study were as follows: (1) to determine whether the location of the metabolic epicenter of a supratentorial glioma is related to survival; and, (2) to determine if a relationship exists between the location of the metabolic epicenter of a supratentorial glioma and its histopathological grade.
MATERIALS AND METHODS

Subjects
We examined the hospital and clinic charts of 60 consecutive patients starting in May 1999 who were diagnosed as having a supratentorial glioma and who were included in the 1 H-MRSI brain tumor database at the Montreal Neurological Institute and Hospital (MNI). Patients were included in the study only if they had been closely followed in our brain tumor clinic, if their survival information was available (i.e., either exact length of survival or right-censored survival data), and if they had undergone complete 1 H-MRSI examinations. Patients whose eventual outcome was determined largely by complications unrelated to tumor growth rather than by tumor progression alone were excluded. Therefore, three patients who died of intracranial or somatic postoperative complications within 30 days of surgery were excluded. One patient with clearly multifocal glioma was excluded because tumors in all other patients were unifocal. Two patients who died on unknown dates and did not survive for at least 12 months (i.e., leftcensored) were also excluded because the estimate of their length of survival was judged exceedingly imprecise.
The median age of the remaining 54 patients who were included in the study (Table 1) was 44 years (range 19 to 81.4 years). In 51 of these cases, tumors were histologically assessed by a neuropathologist based on tissue samples obtained via an open debulking procedure (n = 30) or via stereotactic biopsy (n = 21). The remaining three patients did not undergo tumor biopsy because their general medical condition was poor. In each of these three cases, however, glioblastoma multiforme (GBM) was confirmed on postmortem neuropathological examination. All study patients were treated according to conventional treatment protocols (e.g., surgical debulking, radiation, and chemotherapy) as deemed appropriate for their histopathologic diagnosis and clinical status.
H-MRSI Acquisition
Each patient underwent pretreatment conventional MRI and 1 H-MRSI scanning. The patients were deemed eligible for 1 H-MRSI because they each had a brain tumor that was considered supratentorial on conventional MRI and was sufficiently large for the 1 H-MRSI study (i.e., at least 1.5 cm in the craniocaudal dimension). Conventional MRIs and two-dimensional multivoxel 1 H-MRSI scans were acquired using a 1.5 Tesla unit (Gyroscan ACS II/III Philips Medical Systems, Best, The Netherlands).
For 1 H-MRSI, a large region of interest (ROI) was defined for selective excitation using standard spin-echo proton densityweighted images (TR/TE = 2100/30 , 250 x 250 mm 2 field of view (FOV), 204 x 256 matrix) in three planes. These ROIs included the entire tumor as well as contralateral or remote normal-appearing brain tissue. The ROIs were aligned parallel to transverse MRI slices and ranged from 70 to 120 mm anteroposteriorly, from 75 to 120 mm mediolaterally, and from 14 to 24 mm craniocaudally. We used a volume- unavailable when the study began. While we did not use an outer-volume lipid-suppression sequence, unwanted lipid signal was avoided by making sure that the edges of the ROIs did not extend into the skull. 1 H-MRSI scans were always obtained before intravenous contrast was administered. In every case, the ROI was determined by the senior author (MCP).
Spectra were obtained using a 90º-180º-180º (i.e., PRESS) pulse sequence for volume selection. Water was suppressed by selective excitation. The following acquisition parameters were used: an interpulse delay (TR) of 2000 ms, a spin-echo refocusing time (TE) of 272 ms, a FOV of 250 x 250 mm 2 , 32 x 32 phase encoding steps, and 1 signal average per phaseencoding step. The water-suppressed 1 H-MRSI image was followed by a nonwater-suppressed image obtained using a TR of 850 ms, a TE of 272 ms, a FOV of 250 x 250 mm 2 , and 16 x 16 phase encoding steps. To correct for artifact arising from inhomogeneities in the magnetic field, the water-suppressed 1 H-MRSI was divided by the unsuppressed 1 H-MRSI after zerofilling the latter to 32 x 32 profiles. This correction yielded a nominal voxel (i.e., tissue volume) size of 0.7ml. Total imaging time, including ROI definition, shimming, gradient tuning, and 1 H-MRSI acquisition, ranged from 55 min to 85 minutes. parts per million (ppm) between the resonant frequency of the compound of interest and that of tetramethylsilane, these five resonances included Cho at 3.2 ppm, creatine at 3.0 ppm, Nacetyl aspartate at 2.0 ppm, lactate at 1.3 ppm, and lipid at 0.9 ppm. Metabolite resonance intensities were determined by the area of Gaussian line-shapes, which were fitted to the resonance peaks relative to a baseline computed from a moving average of the noise regions of each spectrum. Only voxels fully within the tumor mass as outlined on conventional T2-weighted MRI were considered for inclusion in the study. Presumed areas of cyst or necrosis were excluded. In each case the voxel containing maximum intratumoral Cho (max Cho) was identified -this was the metabolic epicenter.
H-MRSI Postprocessing
Definition of a Standardized Coordinate System
We used a three-dimensional Cartesian system to describe the location of the metabolic epicenter using X, Y, and Z coordinates. The X coordinate described the mediolateral position, the Y coordinate described the anteroposterior position, and the Z coordinate described the craniocaudal position. The intersection of the X, Y, and Z axes represented the geometric midpoint of the brain and was called the cerebral zero point.
Because of variations in head position and brain shape among patients, the coordinates of the metabolic epicenter in each patient were determined as follows. First, an in-house featurematching algorithm was used to match the axial 1 H-MRSI slice containing the metabolic epicenter anatomically to a corresponding slice generated by a validated MRI simulator developed at the Montreal Neurological Institute. 30 The position assigned to this slice by the simulator became the Z coordinate (Figure1A). In our system, the Z coordinate of the metabolic epicenter was the distance, measured in number of axial slices, between the craniocaudal midpoint of a theoretical "average" brain and the slice containing the max Cho voxel.
On this same slice, the Y axis was set along the cerebral midline, and the X axis was set perpendicular to the Y axis. X and Y coordinates for the metabolic epicenter were then determined by dividing the projection of the metabolic epicenter onto the X and Y axes by the length of each respective axis ( Figure 1B) . No direction was chosen as negative along any axis, since we were interested in assessing variations in the absolute distance of the metabolic epicenter from the zero point.
Statistical Analysis
Cox proportional hazards regression analysis was performed to generate a model correlating survival with the X, Y, and Z coordinates of the metabolic epicenter. The amount of variability (r 2 ) in the dependent variable (i.e., survival) accounted for by the independent variable (i.e., metabolic epicenter location) was determined, and the goodness-of-fit of the model was evaluated by performing Chi-squared (χ 2 ) analysis. To determine whether metabolic epicenter location carried any prognostically significant information independent of histopathological grade, tumor grade was added as a feature in a second model. Feature significance and goodness-of-fit were then recomputed. Astrocytomas and oligodendrogliomas, while sharing some common glial lineage, nonetheless behave much differently in most clinical situations, with astrocytomas tending to behave more aggressively for a given WHO grade. For this reason, we also repeated our analyses on the subgroup of astrocytomas alone. We controlled for age and KPS at diagnosis in all models.
The absolute distance of the metabolic epicenter from the zero point was computed for each patient using the formula: 
Ethics Approval
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RESULTS
Patient Survival and Tumor Histopathological Grade
Patients survived for a median length of 26.8 months (range 0.2-110.9 months) after 1 H-MRSI examination. Based on histopathological analysis, 35% (n = 19) of the tumors were WHO grade II, 26% (n = 14) were grade III, and 39% (n = 21) were grade IV (Table 1) . For the subgroup of astrocytomas, median survival was 11.7 months (range 0.2 -108.7 months), with 24% (n = 9) grade II, 19% (n = 7) grade III and 57% (n = 21) grade IV.
Metabolic Epicenter Location: Raw Data
Raw X, Y, and Z coordinates of the max Cho voxel are reported for each patient in Table 1 .
Metabolic Epicenter Location and Survival
The results of Cox proportional hazards regression analysis are summarized in Table 2 . In correlating metabolic epicenter location to survival, the best regression model included as features the X coordinate, the Z coordinate, and the product of the X and Z coordinates, also known as the XZ interaction term. The Y coordinate was not significant in this model. The model fit the survival data significantly better than chance (χ 2 = 19.6, df = 3, p = 0.0002) and was able to account for 30% of the variability in patient survival (r 2 = 0.30). The best model based on histopathological grade alone also fit the data better than chance (χ 2 = 47.4, df = 2, p < 0.0001) and accounted for 58% of the variability in survival (r 2 = 0.58). When grade and metabolic epicenter location were both included as prognostic factors, the best resulting model showed that grade, X coordinate, Z coordinate, and the XZ interaction term all remained significant predictors of survival (p < 0.02), suggesting that metabolic epicenter location and grade are prognostically independent. This combined model fit the survival data best (χ 2 = 69, df = 7, p < 0.0001) and accounted for 70% of variability in survival (r 2 = 0.70). In a subgroup evaluation of only astrocytomas, it was noted that the best model based on distance of the metabolic epicenter alone was able to account for 32% of the variability in patient survival (r 2 = 0.32, p = 0.017), while the best model based on histopathological grade alone accounted for 69% of the variability in survival (r 2 = 0.69, p = 0.001). When all features, including grade and metabolic epicenter location were included, the best model accounted for 73% of the variability, (r 2 = 0.73, p = 0.001), but the X coordinate, Z coordinate and distance to metabolic epicenter were no longer significantly additive as predictors of survival, although there was a trend towards significance, and this was likely the result of a smaller sample size. 
Metabolic Epicenter Location and Tumor Histopathological Grade
The mean normalized distance of the metabolic epicenter from the zero point was 0. For the subgroup of astrocytomas, the mean normalized distance of the metabolic epicenter from the zero point was 0.90 ± 0.058 for grade II, 0.88 ± 0.090 for grade III and 0.69 ± 0.058. One way ANOVA showed the means to be statistically different from each other (p = 0.047) but post-hoc tests failed to show further significant trends, likely due to the smaller group sizes. When grade II and III tumors were combined, it was noted that they had a metabolic epicenter further from the zero point than grade IV tumors (p = 0.013).
The results of multinomial logistic regression modeling relating tumor grade to metabolic epicenter location are summarized in Table 3 . The X coordinate, Z coordinate, and XZ interaction term were all significantly related to tumor grade, independently (χ 2 > 10, df = 2, p ≤ 0.008 in all cases) and taken together (χ 2 = 27.5, df = 6, p = 0.0001). The higher grade tumors had a metabolic epicenter location closer to the zero point than their lower grade counterparts (Figure 3 ). When the analysis was repeated for the astrocytoma subgroup alone, the X coordinate and mean normalized distance remained significantly related to tumor grade (χ 2 = 4.8, df = 2, p = 0.029 and χ 2 = 6.5, df = 2, p = 0.011, respectively), but the other interactions terms were no longer significantly related. This likely reflects the small sample size, especially fewer grade III tumors in the astrocytoma subgroup.
DISCUSSION
The results of this study suggest that the location of metabolic epicenter, as defined by the position of the intratumoral voxel containing max Cho on in vivo 1 H-MRSI, is significantly related to length of survival independent of tumor grade. This finding held true for our combined population of glial tumors, and also for a subgroup evaluating only the astrocytomas. To our Table 3 : Results of multinomial logistic regression modeling: significance and regression coefficients of features between spectroscopic tumor location and histopathological grade knowledge, this study is also the first to show a significant relationship between glioma location and histopathological grade, when location is defined by a quantitative, easy to measure surrogate, the metabolic epicenter.
Advantages of Using a Metabolic Definition of Glioma Location
Studies addressing glioma location have usually done so in the context of large multivariate analyses of various prognostic factors and the effects of these factors on outcome. 6, 11, 13, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] In addition, two recent epidemiological studies from Finland 45 and France 46 have examined the incidence of gliomas by location. In most of these studies, tumors are typically classified by their position in the frontal, parietal, temporal, or occipital lobes. 6, 13, [31] [32] [33] [34] [35] [36] [37] [38] [39] 45 Other studies distinguish between tumors that are lobar or nonlobar, 11 superficial or deep, [40] [41] [42] or situated in eloquent versus non-eloquent areas. 46 Devaux et al 43 classified gliomas according to cortical, subcortical, midline, or brainstem locations, while Shinoda et al 44 subdivided location into three subgroups based on the eloquence of the brain underlying the tumor.
Most of these studies found no correlation between glioma location and length of survival, 6, 33, 34, 39, 43, 44 or did not look for the presence of such a correlation. 45, 46 Coffey et al, 11 however, reported that lobar gliomas overall tended to have a better prognosis than nonlobar gliomas. Gehan and Walker 37 found that parietal lobe tumors were associated with shorter survival times than lesions located elsewhere. Among malignant gliomas (i.e., WHO grade II or higher), frontal lobe location also appears to be associated with prolonged survival: Jeremic et al in three separate studies, 13, 33, 34 Simpson et al, 35 and Curran et al 36 found that frontal lobe location independently predicted increased survival times in patients with tumors classified as WHO grade III or higher. Superficial location also may portend a more favorable prognosis, both for GBMs as reported by Jelsma and Bucy, 40, 41 and for malignant gliomas as a whole, as reported by Winger et al. 42 That previous findings on the nature of relationships between brain tumor location and prognosis are conflicting is expected. First, relatively few studies have examined the issue systematically. Furthermore, the lack of a standard descriptive classification system for tumor location makes it difficult to compare individual studies. In this study we used metabolic information, obtained in an automated fashion via 1 H-MRSI, to define tumor location as a single point in space called the metabolic epicenter. This approach removes the possibility of misclassifying, for example, tumors whose margins may be illdefined or that straddle the boundaries between different cerebral lobes. Furthermore, it uses a standardized stereotactic coordinate system, allowing tumor location data to be compared between patients with varying head and brain sizes. Finally, by accounting for the characteristic regional biological and behavioural heterogeneity of gliomas, the approach is able to account for the fact that tumors appearing to arise from the same part of the brain may in fact have different centers of metabolic activity, which may in turn produce differences in their overall growth and impact on survival.
Relationship between Metabolic Epicenter Location and Survival
Our results showed that a superficial metabolic epicenter location was significantly related to increased survival. In contrast, as the metabolic epicenter converged to the midpoint of the brain, length of survival shortened.
Previous studies reporting increased survival times with more superficially located tumors have speculated that such lesions are more surgically accessible and hence more readily resected. 40, 41, 47 There is also mounting evidence that more extensive surgical resection is associated with longer life expectancy in patients with glioma, irrespective of grade. In our study, the location of the metabolic epicenter on pre-operative imaging studies predicted survival independently of other patient factors or tumor grade. 48 This held true in both the combined population of tumors, and in the subgroup comprised only of astrocytomas, and was a robust predictor of survival on its own but also improved the model when combined with other features, strongly supporting the notion that the location of the metabolic epicenter is related to genuine biological and biophysical characteristics of gliomas in the supratentorial compartment. One of the weaknesses of our study is that surgical debulking could not be evaluated because we did not consistently have MRI data from the immediate postoperative period from which residual tumor volume could be calculated. Future studies incorporating objective, volumetric data on the extent of surgical resection in combination with 1 H-MRSI assessment of the metabolic epicenter are needed to determine if surgery has a greater effect on the magnitude of the relationship between metabolic location and survival than we have predicted.
Relationship between Metabolic Epicenter Location and Histopathological Grade
Our finding of a significant relationship between metabolic epicenter location and histopathological grade, implying that the most metabolically active portion of high-grade tumors converges to the midpoint of the brain, is novel and interesting. This finding follows logically from existing studies on glioma expansion and invasion. It is widely accepted that, unlike other brain neoplasms, both benign and malignant gliomas infiltrate surrounding brain parenchyma by contiguous spread from a very early stage in their development. 14 The mechanisms responsible for glioma invasion at the molecular and cellular levels are still a source of intense investigation, but nonetheless patterns common to gross invasion have been observed. Chief among these is that gliomas spread predominantly through white matter tracts, first postulated more than a century ago by Strobe (as cited by Mikkelsen et al) 14 and later detailed during the first half of the 20th century by Scherer. 49 The spread of malignant gliomas through most large white matter tracts, including the corpus callosum, uncinate fasciculus, fasciculus longitudinalis, fasciculus occipitofrontalis, auditory and visual bundles, and the corona radiata, has been documented both pathologically 50 and using conventional MRI. 51, 52 GBMs in particular tend to invade deep supratentorial structures by expanding vertically in the white matter. As many as 20% of GBMs show such invasion at autopsy. 53 Our finding that the highest grade tumors had their metabolic epicenters in the deep white matter closest to the midpoint of the supratentorial space is consistent with these prior observations. It further suggests that supratentorial GBMs may be more likely to originate and expand from foci within the deep white matter of the cerebral hemispheres.
Malignant degeneration or dedifferentiation leading to recurrence at a higher histopathological grade is a well-described phenomenon in low-grade gliomas. Its incidence is estimated at 13 to 86%. [54] [55] [56] [57] [58] [59] [60] Our data suggest that the acquisition of increasing histological malignancy, detected microscopically, may be accompanied by a stereotyped, macroscopic glioma growth pattern in the supratentorial compartment. Conceivably, as a low-grade tumor dedifferentiates, it may invade in a preferentially deeper direction. The result would be a high-grade tumor with its metabolic epicenter positioned closer to the cerebral zero point. A more interesting explanation is that even if growth by a low-grade glioma occurs equally in all directions, tumor cells may have a tendency to become malignant only when they reach deeper locations in the cerebral hemispheres. This would imply that location may be a determinant of histology, a hypothesis that has previously been suggested, 46 and for which evidence is mounting as investigators examine deep locationssuch as the subventricular zone-thought to contain neural stem cells which may give rise to GBM. 61 The preponderantly deep metabolic epicenters of grade IV tumors that we observed might be explained by the existence of a biochemical milieu in these deep locations favouring the development of GBMs, whether arising de novo or secondarily.
Preliminary serial 1 H-MRSI assessments in selected patients at our center do in fact suggest that the metabolic epicenter of a tumor migrates toward the cerebral zero point as it develops increasingly malignant histology (Figure 4 ). This phenomenon may eventually have implications in predicting patterns of glioma recurrence and in designing appropriate targeting strategies for radiotherapy. In particular, it suggests that attacking large superficial portions of a glioma with surgery or radiation may not be of benefit if the deep metabolic epicenter is left intact. Of course this prediction needs to be confirmed in rigorous prospective studies tracking the location of the metabolic epicenter over time in individual patients. In addition, it will be important to study the relationship of metabolic epicenter to behaviour across other tumor types.
We have demonstrated a novel method of assessing supratentorial glioma location by defining the so-called metabolic epicenter in a series of patients as the coordinate position of the voxel containing maximum intratumoral Cho on 1 H-MRSI scanning. The concept of the metabolic epicenter eliminates several of the problems related to existing methods of classifying glioma location. Furthermore, our finding that the location of the metabolic epicenter is strongly correlated with overall survival and histopathological grade, suggests that it is reflective of biological factors which influence glioma genesis, expansion, and malignant dedifferentiation. Our findings point to clinical implications in predicting patterns of local tumor recurrence, and in planning resective surgery and radiotherapy. 
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